Economics of gastroenteropancreatic neuroendocrine tumors: a systematic review.
budget impact
cost-of-illness
costs
economic burden
economic evaluation
gastroenteropancreatic neuroendocrine tumors
resource utilization
systematic review
Journal
Therapeutic advances in endocrinology and metabolism
ISSN: 2042-0188
Titre abrégé: Ther Adv Endocrinol Metab
Pays: United States
ID NLM: 101532143
Informations de publication
Date de publication:
2019
2019
Historique:
received:
19
10
2018
accepted:
13
01
2019
entrez:
1
3
2019
pubmed:
1
3
2019
medline:
1
3
2019
Statut:
epublish
Résumé
Despite current interest, enthusiasm and progress in the development of therapies for gastroenteropancreatic (GEP) neuroendocrine tumors (NETs), there are substantial gaps in the published literature regarding cost-of-illness analyses, economic evaluation and budget impact analyses. Compounding the issue is that data on resource utilization and cost-effectiveness of different diagnostic and therapeutic modalities for GEP-NETs are scarce. A systematic review on the economic impact of GEP-NETs was carried out using four databases: The 14 studies selected included cost-of-illness analyses ( There is a lack of data related to resource utilization in the field of GEP-NETs. Therefore, cost-effectiveness and budget impact studies of existing and emerging treatments are urgently needed to help the decision-making process for patients with NETs.
Sections du résumé
BACKGROUND
BACKGROUND
Despite current interest, enthusiasm and progress in the development of therapies for gastroenteropancreatic (GEP) neuroendocrine tumors (NETs), there are substantial gaps in the published literature regarding cost-of-illness analyses, economic evaluation and budget impact analyses. Compounding the issue is that data on resource utilization and cost-effectiveness of different diagnostic and therapeutic modalities for GEP-NETs are scarce.
METHODS
METHODS
A systematic review on the economic impact of GEP-NETs was carried out using four databases:
RESULTS
RESULTS
The 14 studies selected included cost-of-illness analyses (
CONCLUSION
CONCLUSIONS
There is a lack of data related to resource utilization in the field of GEP-NETs. Therefore, cost-effectiveness and budget impact studies of existing and emerging treatments are urgently needed to help the decision-making process for patients with NETs.
Identifiants
pubmed: 30815246
doi: 10.1177/2042018819828217
pii: 10.1177_2042018819828217
pmc: PMC6381439
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
2042018819828217Déclaration de conflit d'intérêts
Conflict of interest statement: E.G. received honoraria as a speaker, and participated in advisory boards at Novartis, Pfizer, IPSE, Adacap and Lexicon. All other authors have no conflicts of interest to declare.
Références
Pharmacoeconomics. 2001;19(6):609-21
pubmed: 11456210
Cancer. 2003 Feb 15;97(4):934-59
pubmed: 12569593
Surgery. 2003 Dec;134(6):1057-63; discussion 1063-5
pubmed: 14668741
Gut. 2005 Jun;54 Suppl 4:iv1-16
pubmed: 15888809
Pancreatology. 2009;9(5):583-600
pubmed: 19657214
J Clin Oncol. 2009 Oct 1;27(28):4656-63
pubmed: 19704057
Int J Surg. 2010;8(5):336-41
pubmed: 20171303
N Engl J Med. 2011 Feb 10;364(6):501-13
pubmed: 21306237
N Engl J Med. 2011 Feb 10;364(6):514-23
pubmed: 21306238
Eur J Health Econ. 2011 Dec;12(6):499-502
pubmed: 21874376
Pancreas. 2012 Oct;41(7):1058-62
pubmed: 22513292
J Cancer. 2012;3:292-302
pubmed: 22773933
J Med Econ. 2012;15 Suppl 1:55-64
pubmed: 22881362
Med Devices (Auckl). 2012;5:39-44
pubmed: 23166456
World J Gastroenterol. 2013 Apr 21;19(15):2348-54
pubmed: 23613628
Eur J Cancer Care (Engl). 2013 Nov;22(6):714-25
pubmed: 23895457
Value Health. 2014 Jan-Feb;17(1):5-14
pubmed: 24438712
N Engl J Med. 2014 Jul 17;371(3):224-33
pubmed: 25014687
J Med Econ. 2015 Feb;18(2):126-36
pubmed: 25325180
Contemp Oncol (Pozn). 2014;18(6):442-7
pubmed: 25784845
Surgery. 2015 Aug;158(2):339-48
pubmed: 25999251
Br J Surg. 2016 Feb;103(3):226-32
pubmed: 26511392
Endocr Relat Cancer. 2016 Mar;23(3):191-9
pubmed: 26743120
World J Gastroenterol. 2016 Feb 14;22(6):2118-25
pubmed: 26877616
Support Care Cancer. 2016 Sep;24(9):3695-703
pubmed: 27029477
Endocr Pract. 2016 Sep;22(9):1068-80
pubmed: 27214300
J Clin Oncol. 2017 Jan;35(1):14-23
pubmed: 27918724
J Med Econ. 2017 Apr;20(4):395-404
pubmed: 27981858
JAMA Oncol. 2017 Oct 1;3(10):1335-1342
pubmed: 28448665
J Med Econ. 2017 Sep;20(9):945-951
pubmed: 28562131
Ann Surg Oncol. 2017 Oct;24(11):3312-3323
pubmed: 28695392
Clinicoecon Outcomes Res. 2017 Aug 16;9:495-503
pubmed: 28860831
J Med Econ. 2018 Feb;21(2):182-188
pubmed: 28959913
Clin Ther. 2017 Dec;39(12):2338-2344
pubmed: 29175096
Am Health Drug Benefits. 2017 Nov;10(8):408-415
pubmed: 29263774
Endocr Relat Cancer. 2018 Mar;25(3):309-322
pubmed: 29330194
Curr Oncol. 2018 Feb;25(1):32-40
pubmed: 29507481
Value Health Reg Issues. 2012 Dec;1(2):150-155
pubmed: 29702894